regeneron semaglutide Readout Newsletter: Amgen, Regeneron, Wegovy/Ozempic news NHP data from $Regeneron Pharmaceuticals

This design choice was deliberate

Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts

The SHP provides health care coverage to nearly 750,000 teachers, state employees, retirees, and their dependents

FDAs scientists (the ones who survived the agencys recent budgetary decimation) looked carefully at each of the substances and determined that they lacked clear evidence of effectiveness or safety